Tefina, a 'female Viagra', currently being studied

November 19, 2012
Tefina, a ‘female Viagra’, currently being studied
Credit: Aleksandar Todorovic - Fotolia.com

Tefina, the first testosterone based intranasal gel, has been in part developed by the ULg's Galenic Pharmacy Laboratory. It is currently at the stage of testing before being marketed by the Canadian company, Trimel Pharmaceuticals.

The University of Liège's Galenic pharmacy laboratory, directed by Professor Brigitte Evrard, is contributing to the development of the Tefina gel, the first testosterone based intranasal gel. It should be injected, in the form of a , one to two hours before . The nose being an organ rich in , it enables a rapid and targeted absorption of the .

The Liège researchers have been working jointly for two years with the Canadian company, Trimel Pharmaceuticals in the context of developing Tefina. This new drug, which constitutes treatment for female anorgasmia – the impossibility of having an orgasm due to organic, behavioural or psychological reasons – is currently undergoing phase 2 clinical trials in the United States, Canada and Australia. The Canadian company which wants to launch on the market a treatment capable of stimulating desire in women, turned to the Liège laboratory to optimise the product

The University of Liège's Galenic pharmacy laboratory thus developed the composition and formula of an intranasal gel so that a sufficient quantity of testosterone can be administered in a single dose, whilst maintaining the integrity of the nasal epithelium. To ensure optimal activity of the active ingredient it was necessary to solubilise and stabilise it, which proved a genuine challenge for the researchers. The was also studied at the laboratory, which is known for innovating and optimising industrial drug manufacturing processes.

Explore further: 'Viagra for women' being trialed

Related Stories

'Viagra for women' being trialed

October 29, 2012

Reaching orgasm remains elusive for nearly 30 per cent of women, but a new ad hoc treatment currently under trial, may drastically reduce that number.

Recommended for you

Researchers identify source of opioids' side effects

January 17, 2017

A commercially available drug may help drastically reduce two side effects of opioid painkillers—a growing tolerance and a paradoxical increased sensitivity to pain—without affecting the drugs' ability to reduce pain, ...

CVS generic competitor to EpiPen, sold at a 6th the price

January 12, 2017

CVS is now selling a rival, generic version of Mylan's EpiPen at about a sixth of its price, just months after the maker of the life-saving allergy treatment was eviscerated before Congress because of its soaring cost to ...

Many misuse OTC sleep aids: survey

December 29, 2016

(HealthDay)—People struggling with insomnia often turn to non-prescription sleep remedies that may be habit-forming and are only intended for short-term use, according to a new Consumer Reports survey.

The pill won't kill your sexual desire, researchers say

December 15, 2016

Taking the pill doesn't lower your sexual desire, contrary to popular belief, according to research published in the Journal of Sexual Medicine. The authors of the research, from the University of Kentucky and Indiana University ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Tausch
1 / 5 (2) Nov 19, 2012
A new twist to all men are created equal.
Sexual 'equality'?
Oops. Strictly business here.
No selfless, starry-eyed ideals to propagate.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.